The same group further reported that crosslinking PD-L1 on tumor cells with multivalent PD-L1 antagonist peptide–HPMA conjugates triggered the lysosomal degradation of PD-L1, outperforming an anti-PD-L1 antibody in its ability to prevent tumor relapse after administration of chemotherapy [304]. The gene discussed is CD274; the disease is neoplasm.